MANCHESTER, Conn., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a Lydall subsidiary, (NYSE:LDL) announced today that it has established a strategic partnership with CELLution Biotech B.V., an innovative developer and provider of bioreactors and fermenters based in the Netherlands. By combining their respective expertise in single-use technology and mass transfer, the partnership will provide customers in North America and Europe with turnkey single-use solutions for fermentation and perfusion cell growth.
CELLution Biotech's CELL-tainer® products are used to perform high-density fermentation, making it the ideal tool for seed train development while operating in a single-use environment. CELLution Biotech's bioreactors can also be used in the application of mammalian cell culture perfusion given its superior mass transfer performance coupled with a unique channeling system. This high level of performance enables the advantages of single-use technology to be applicable to the microbial fermentation and perfusion cell culture market segments where they are not commonly used today.
Charter Medical, a Lydall company, will be the exclusive distributor of the CELL-tainer® products as well as exclusive producer and supplier of Charter Medical's single-use bags utilized in conjunction with CELLution's systems. Charter Medical will leverage its established customer relationships and strong network to sell these complementary products across North America and Europe.
Dale Barnhart, President and CEO of Lydall, stated: "We are very excited about this opportunity as it takes advantage of Charter Medical's expertise in single-use products and helps transform our business into a more complete solution provider to the bioprocessing industry we currently serve today."
Hans Walraven, CEO of CELLution, commented that "CELLution is proud to enter this strategic alliance with such outstanding, complementary partners. It certainly will boost the power of single-use solutions to our customers, in particular for new applications."
APIcells Inc. will complement the partnership between Charter Medical and CELLution by supporting the service of the systems as well as bringing additional upstream process engineering expertise, enabling customers to tailor the instrumentation and controls around the CELL-tainer® technology and their process requirements.
About Lydall, Inc.
Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, the Netherlands and Germany and offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. Charter Medical, Ltd., a Lydall subsidiary, is a vital fluids management company focused on providing products to separate, contain and transport vital fluids in the blood and cell therapy market and the biotech and pharmaceutical industries. Lydall® is a registered trademark of Lydall, Inc. in the U.S. and other countries. All product names are trademarks of Lydall, Inc. or Charter Medical, Ltd.
CONTACT: For further Charter Medical Information: Gael Peron Director Sales & Marketing 3948-A Westpoint Blvd. Winston-Salem, NC 27103 Phone: +33 6 38 18 41 12 Fax: (336) 774-1750 email@example.com www.chartermedical.com For further information: David D. Glenn Director Business Development and Investor Relations Telephone 860-646-1233 Facsimile 860-646-4917 firstname.lastname@example.org www.lydall.com